Current and future clinical strategies in colon cancer prevention and the emerging role of chemoprevention
- PMID: 17692000
- DOI: 10.2174/138161207781368783
Current and future clinical strategies in colon cancer prevention and the emerging role of chemoprevention
Abstract
In the third millennium preventive medicine is becoming a corner stone in our concept of health. Colorectal cancer (CRC) fits the criteria of a disease suitable for prevention interventions. It is a prevalent disease that is associated with considerable mortality and morbidity rates, with more than 1,000,000 new cases and 500,000 deaths annually. CRC has a natural history of transition from precursor to malignant lesion that spans, on average, 10-15 years, providing a window of opportunity for effective interventions and prevention. Indeed, CRC is preventable in up to 90% of the cases. Simple life style modifications (balanced diet avoidance of smoking and alcohol, and moderate physical activity) can prevent up to 50% of the cases of colorectal cancer. Compliance with current screening methods is a major barrier to the achievement of optimal results, a large part of the average risk population has not been screened by any method. Several newly developed screening modalities, such as the virtual colonoscopy and stool genetic testing may improve compliance. In addition, chemoprevention, a new science that has emerged during the last decade, presents an alternative approach to reducing mortality from colorectal cancer as well as other cancers. Chemoprevention involves the long-term use of a variety of oral agents that can delay, prevent or even reverse the development of adenomas in the large bowel. In light of the recent evidence of the efficacy of chemoprevention in persons at high risk for CRC cancer, it seems only appropriate to consider similar strategies for the general population.
Similar articles
-
Chemoprevention of colorectal cancer: ready for routine use?Curr Top Med Chem. 2005;5(5):517-25. doi: 10.2174/1568026054201659. Curr Top Med Chem. 2005. PMID: 15974946 Review.
-
Cyclooxygenase-2 as target for chemopreventive interventions: new approaches.Cancer Biomark. 2007;3(3):153-61. doi: 10.3233/cbm-2007-3306. Cancer Biomark. 2007. PMID: 17611306 Review.
-
Chemoprevention of colorectal cancer: ready for routine use?Recent Results Cancer Res. 2005;166:213-30. doi: 10.1007/3-540-26980-0_14. Recent Results Cancer Res. 2005. PMID: 15648192 Review.
-
Colon cancer: preventive agents and the present status of chemoprevention.Expert Opin Pharmacother. 2009 Feb;10(2):211-9. doi: 10.1517/14656560802560153. Expert Opin Pharmacother. 2009. PMID: 19236194 Review.
-
Chemoprevention of colorectal cancer.Digestion. 2007;76(1):51-67. doi: 10.1159/000108394. Epub 2007 Oct 19. Digestion. 2007. PMID: 17947819 Review.
Cited by
-
Cardiovascular medication use and risk for colorectal cancer.Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3076-80. doi: 10.1158/1055-9965.EPI-08-0095. Epub 2008 Oct 28. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18957524 Free PMC article.
-
Determination of anticancer potential of a novel pharmacologically active thiosemicarbazone derivative against colorectal cancer cell lines.Saudi Pharm J. 2022 Jun;30(6):815-824. doi: 10.1016/j.jsps.2022.03.011. Epub 2022 Mar 31. Saudi Pharm J. 2022. PMID: 35812146 Free PMC article.
-
A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.Trials. 2013 Jul 29;14:237. doi: 10.1186/1745-6215-14-237. Trials. 2013. PMID: 23895505 Free PMC article. Clinical Trial.
-
Altered gene expression and miRNA expression associated with cancerous IEC-6 cell transformed by MNNG.J Exp Clin Cancer Res. 2009 Apr 28;28(1):56. doi: 10.1186/1756-9966-28-56. J Exp Clin Cancer Res. 2009. PMID: 19397828 Free PMC article.
-
Highly Correlated Recurrence Prognosis in Patients with Metastatic Colorectal Cancer by Synergistic Consideration of Circulating Tumor Cells/Microemboli and Tumor Markers CEA/CA19-9.Cells. 2021 May 10;10(5):1149. doi: 10.3390/cells10051149. Cells. 2021. PMID: 34068719 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical